Site Navigation

Our Technology

VasGene is focused initially on the development of three patent protected drugs based on its vascular biology expertise, with other potential products in research:

Key Product Pipline Status
Product Name Description Advantage Stage of Development
Veglin: VEGF Anti-sense molecule.
Click Here for more information.		 Therapeutic drug for the treatment of advanced cancers with both growth inhibitory and anti-angiogenic properties. Veglin is unique in the class of VEGF inhibitors under development by blocking production of all VEGF isoforms including VEGF-A, VEGF-C, as well as VEGF-D. Veglin attacks tumor growth and metastasis on three fronts: direct tumor cell growth inhibition, new tumor blood vessel formation, and invasion and lymphatic spread of tumor cells to distant sites. Clinical: A Phase I Study of Veglin in the treatment of patients with relapsed or refractory malignancies at the USC/Norris Comprehensive Cancer Center and USC-Los Angeles County Medical Centers is nearly complete. Phase II trials are targeted for initiation in Q4 2004.
Ephrin B2/EphB4 antagonists/Cancer and Ophthalmology: Soluble receptors, monoclonal antibodies, and antisense oligonucleotides.
Click Here for more information.		 Therapeutic drugs for inhibiting growth and constricting blood supply to tumors and preventing angiogenesis in eye diseases. Compounds for treating cancer through inhibition of multiple angiogenesis pathways. Blocking multiple pathways more efficacious than blocking a single pathway. Preclinical: Completing testing of recombinant molecules. To be followed by cGMP manufacturing, pre-clinical animal toxicology and pharmacology studies.
VAS012: Multifunctional amine derivative.
Click Here for more information.		 Small molecule compound belonging to a novel structure class of anticancer agents that is selectively cytotoxic to proliferating endothelial cells. Induction of immune response against multiple tumor antigens minimizes tumor escape. Defined pharmaceutical composition. Preclinical: Completing lead optimization and structure activity relationships in anticipation of product development activities.